#United States #Charles C. Foti #New Orleans #Kahn Swick Foti #Soleno Therapeutics

Important Notice for Investors in Soleno Therapeutics

Investors in Soleno Therapeutics, Inc. should be aware of an upcoming application deadline for a class action lawsuit related to alleged securities fraud. Kahn Swick Foti, LLC (KSF) has announced that investors have until May 5, 2026 to submit their applications for appointment as lead plaintiff in the case against Soleno Therapeutics. This legal action addresses concerns regarding potential misleading statements made by the company during a crucial period for investors.

Background Information

The class action lawsuit targets investors who held shares in Soleno during the period from March 26, 2025, to November 4, 2025. The Complaint alleges that key executives at Soleno failed to disclose vital information concerning potential safety risks associated with the company's only commercial product, DCCR. This product is intended for treating hyperphagia in individuals suffering from Prader-Willi syndrome (PWS).

The complaint also outlines several alleged violations of federal securities laws. These include accusations that the company and its executives misrepresented or overlooked critical safety concerns during clinical trials — specifically the risk of excessive fluid retention observed in participants. Investors are concerned that this negligence rendered DCCR riskier for patients than previously disclosed.

Implications for Investors

The legal action underscores the necessity for investors to be vigilant regarding their rights, especially when corporate malfeasance or misrepresentation is suspected. The allegations imply that investors could face significant financial losses if the situation is not addressed adequately. Because of these potential risks, being part of the lead plaintiff cohort may enhance an investor's position in any recovery that could follow a successful resolution of the case.

As part of the legal process, KSF advises all affected investors to consider their options before the deadline of May 5, 2026. Investors are encouraged to contact KSF's Managing Partner, Lewis Kahn, either via telephone at 1-877-515-1850 or through email at email protected]. They can also access further details by visiting [KSF's official website.

About Kahn Swick Foti, LLC

KSF, a distinguished securities litigation law firm led by former Louisiana Attorney General Charles C. Foti, Jr., specializes in advocating for investors facing losses due to corporate wrongdoing. The firm has achieved national recognition for its successful settlements and their authoritative stance in securing returns for clients — public entities, private investors, and retail shareholders alike. KSF maintains offices across major cities including New York, Delaware, California, Louisiana, and Chicago, ensuring they are well-positioned to address client needs effectively.

As the lawsuit develops, affected investors should remain informed about their situation and take appropriate steps to seek justice and compensation for any losses sustained during the period in question. This is a crucial moment for Soleno investors to act, as their involvement in the class action can make a significant difference in the outcome of the claims against the company.

Investors should stay connected with KSF as they navigate through these proceedings, ensuring they maximize their chances of recovery. The landscape for investors and the situation at Soleno Therapeutics will continue to evolve, and staying updated will be key.

For further updates and details about the case, be sure to follow KSF's communications or reach out directly for support. The deadline is approaching, and prompt action is essential.